ATOSSA THERAPEUTICS I

NetDania - New 12 months Low: ATOSSA THERAPEUTICS INC. - COMMON STOCK

07 Apr 2025 09:45:25 By NetDania Notify

NetDania - New 12 months Low: ATOSSA THERAPEUTICS INC. - COMMON STOCK

04 Apr 2025 09:47:46 By NetDania Notify

NetDania - New 12 months Low: ATOSSA THERAPEUTICS INC. - COMMON STOCK

03 Apr 2025 10:51:51 By NetDania Notify

NetDania - New 12 months Low: ATOSSA THERAPEUTICS INC. - COMMON STOCK

01 Apr 2025 14:19:20 By NetDania Notify

Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

25 Mar 2025 08:00:01 By Nasdaq GlobeNewswire

Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

20 Mar 2025 09:13:10 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: ATOSSA THERAPEUTICS INC. - COMMON STOCK

13 Mar 2025 10:46:39 By NetDania Notify

NetDania - New 12 months Low: ATOSSA THERAPEUTICS INC. - COMMON STOCK

12 Mar 2025 13:17:26 By NetDania Notify

Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications

11 Mar 2025 08:15:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: ATOSSA THERAPEUTICS INC. - COMMON STOCK

10 Mar 2025 15:12:07 By NetDania Notify

NetDania - New 12 months Low: ATOSSA THERAPEUTICS INC. - COMMON STOCK

04 Mar 2025 09:45:49 By NetDania Notify

Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care

05 Feb 2025 08:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: ATOSSA THERAPEUTICS INC. - COMMON STOCK

30 Jan 2025 09:45:02 By NetDania Notify

Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591

30 Jan 2025 08:17:09 By Nasdaq GlobeNewswire

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025

23 Jan 2025 08:15:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Applauds U.S. Surgeon General’s Advisory Highlighting Alcohol as a Leading Preventable Cause of Breast Cancer

06 Jan 2025 09:00:00 By Nasdaq GlobeNewswire

Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium

12 Dec 2024 08:15:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density

11 Dec 2024 08:15:00 By Nasdaq GlobeNewswire

Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium

10 Dec 2024 09:05:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research

09 Dec 2024 08:15:00 By Nasdaq GlobeNewswire